RDB07830 - pGL3-AID R2 del.-01

Please check terms and conditions set forth by the depositor, which are specified in the RIKEN BRC Catalog and/or Web Catalog.

Terms and conditions set forth by the DEPOSITOR	In publishing the research results obtained by use of the BIOLOGICAL RESOURCE, a citation of literature(s) designated by the DEPOSITOR is requested. (Nat. Immunol., 11, 148-154 (2010)). In publishing the research results to be obtained by use of the BIOLOGICAL RESOURCE, an acknowledgment to the DEPOSITOR is requested. The availability of the BIOLOGICAL RESOURCE is limited to a RECIPIENT of a not-for profit institution for a not-for-profit research. For use of the BIOLOGICAL RESOURCE by a for-profit institution, the RECIPIENT must reach agreement on terms and conditions of use of it with DEPOSITOR and must obtain a prior written consent from the DEPOSITOR. RECIPIENT must contact the DEPOSITOR in the case of application for any patents or commercial use based on the results from the use of the BIOLOGICAL RESOURCE.
Additional terms and conditions for distribution	The use of the BIOLOGICAL RESOURCE is restricted to the academic researches conducted by non-profit organization. By using this material, the RECIPIENT agrees to be bound by the conditions of the limited use statement of the Promega Corporation.
Ordering	Please visit Information of Request for Distribution.[link] Order form [Credit Card Payment] [Bank Transfer Payment] Material Transfer Agreement (MTA for use for not-for-profit academic purpose) [Word]

提供案内 (日本国内)

[open/close]

提供条件	利用者は、研究成果の公表にあたって寄託者の指定する文献を引用する (Nat. Immunol., 11, 148-154 (2010))。利用者は、研究成果の公表にあたって謝辞の表明を必要とする。　学術機関の学術研究に限る。　営利機関の利用希望者は、事前に利用条件等につき寄託者と合意し、提供承諾を得ること。　利用者が本件リソースを使用して得られた研究成果に基づき特許等の申請、及び事業活動を行う場合は、寄託者と別途協議を行う。
付加的提供条件	本件リソースの使用は学術機関での学術研究に限る。本件リソースの使用にあたって、利用者はプロメガ社の限定使用条件に従う必要がある。
提供依頼	手続きの詳細は、「提供申込みについて[link]」をご覧ください。提供依頼書 [Word] 提供同意書 (MTA、非営利機関による非営利学術研究用)[Word]

References and tips

Sequence information

Catalog #	Resource name	Shipping form	Fee (non-profit org.)
RDB07830	pGL3-AID R2 del.-01	DNA solution

original	Tran, T.H., B cell-specific and stimulation-responsive enhancers derepress Aicda by overcoming the effects of silencers. Nat. Immunol., 11, 148-154 (2010). PMID 19966806.

RIKEN BRC has sequenced portions of this material for quality test.
Please review the QC test results indicated by check

icon as well as clone information before placing your order.

Primer: ME-1290Rv Sequence file: RDB07830_A4Gia.seq
>07830_07830_A4Gi_ME_1290Rv_F11_17.ab1 1 ATGGCATTCA TTTTATGTTT CAGGTTCAGG GGGAGGTGTG GGAGGTTTTT TAAAGCAAGT 61 AAAACCTCTA CAAATGTGGT AAAATCGATA AGGATCCACC TAACTCTGAC CACGAAGTTC 121 TTCCCTTCCC CCGGTTTCTC TCTTCTCTGT GTTGCTAGAG ATAGGAAGCC TTGACTTGTC 181 CTGAGATTTG GGCAGAGCTA GAGCCGGCTT GTGGTAATAA CAGTGAAGCC TTAGAGGCCC 241 GCGCCACAAA GAGGTCGTAG CAACTCCTTA CTAAAAACAG TAGTGGTTAT TTTCACAATT 301 ATTTGGCAAA TATCCAACAT CTTAAGACTC GCATGGGGAG TCTTTACAGG AATTATTTAG 361 TTATAGCAAG AAGATTTGTA CTTCTCAAAA AAAAAAAAAA CTAAACATTT GAGATGAATT 421 GCTTGCAACT CATTACAATG GTGTCTATTG AAGGAGAGAA TTTCATTAAG ACAGGCAATT 481 TAGTGTTATA GACTCAACTG TTAGACACTT GGTGACATTT TTACTGTTTA ATTCATCTAT 541 GCAAAGATTT CTTAGCTTCT TGAAAGCTTT TATATGCAGC TCATGATGAG CCATTATCAG 601 AAATTTCTCT CTTGATTTTT ACATTTATTG CCAGTGTGTG AGTCACTATG CCTAAAGCCC 661 ATACACTTGA GCTCACTTCC GTTTGGCTAT GAGGTTTAGA ATATGGAGTT AATATAGCTA 721 ATGGTAGCAG GGTGTTCTTC AGATTCCAGA TTTTTCCTTT CTTGTCTTCC TTCTTTCTTT 781 TTGTTACCCT TCTCCTACCC CCTCTTCTTC TCCCCCTCCT CCTCTTCCTC CCTCCTCCCC 841 ATCTCTTCCC TTCCTCTTCT CCCTCCTCCC CCTCCTCTTC CCCTTCTCCA CTTCCCCCTC 901 TTCCTCCTCT TCCTCCTCCT TCTCCTGCTC CCCATCTCTT TCCCTCCTCT TCTCCCTCCT 961 CCTCCTCCTT TTGCCCCTTC TCCTCTTCCC CCTCCTCCTC TTCCTTTTCC CTTCTCCTCC 1021 TTCTCCTCCC CCTCTCCTCC CCCTTTCTCT CCCACTCTCC TCACCCCCTA TCAGCACCCA 1081 CATTGAAGAC CCTCACCACA TGGCTTAGAC AAGTAATCTG CCCACTTAAC TTACATCCTT 1141 GAAGTCCTTG AATGCAACAG ACTGAACGGC AACGGGGAAA CG //
Primer: pGL3_RV4 Sequence file: RDB07830_A4Gib.seq
>07830_07830_A4Gi_Rv4_G11_20.ab1 1 GCAGGACGAT GGGTTGAGGC TCTCAAGGGC ATCGGTCGAC GGATCCCCCC TCAACTCTAG 61 CTAGGAGCCT ATTTCCAGCT CCCTCTCCTC GGGATGTCCC TCCCGGTAAG GAGGACTTTG 121 CTAGGTGGTG TCCCAAACCT GTAGATCGCC AGCTGCTGAG ACAGCTGTGC TCCTTGAGGC 181 AGAACCTTAG CTGCTTCCCC AGCAATGCAA ACCAGACTCA AGGGGTTAAA AATAATCCCA 241 GCCTAGTAGC AGGGCTGCCT TGAGTTACTC GCTGCCCTTG CTCCAGTCCG TGCCGTGCCA 301 TCCTGTGTCT CTCCACTGTC TTGTTTGCTT CTCCCTGAAT CTCAGCCTCG TCTTTGCTTT 361 GCATTTTGCC ATGCTCATGC ATTTCTCTCG GACCCTTCTC CATCAGGACA TAGATCTCAG 421 ATTTGGTTTC AAAATTCACT ATAAACCCAG AAGCAGCTCA GGCTGTCTGC CTGCCTCCTG 481 TGAACATTTG TTTGTTTGTC TGTCTGTCTG TCTGTCTGTC TGTCTGTCTG TTTGCTTTTT 541 GAGGGCTCAG GATGTAATTA AGTGGCAGAT TACTTGTCTA GCATGTGTGA GGTCTTCAAT 601 GTGGTCCCTG ATAGGGGTGA GGGAGAGTGG GAGGAGGAAA GGGGGAGGAG AGGGGGGATG 661 AGTCGGCCGA TGCGGTTGAG AGCCTTGAAC ACAGTCAGCT CCTTCCAGGT GCACGAGGAG 721 GAGGAGGAGG GAGAAGAGGA GGGAAAGAGA TGGGGAGCAG GAGAAGGAGG AGGAAAGAGG 781 AGGAAGAGGG GGAAGAGGAG AAGGGGAAGA GGAGGGGGGA GGGAGGGGAG AAGAGGAGGG 841 GGATAGATGG GGAGTGGGAG AAACATTCAT ATTTGTTTAA TT //

pGL3-AID R2 del.-01

Distribution information

References and tips

Sequence information

References